CTIS.eu › Cities › Poland › Warsaw
Warsaw
Poland
1,708 total trials
665 recruiting
Filter these 1,708 trials by phase, condition, sponsor and more.
Open in Search →
2024-519917-72-00
5
2025-10-29
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
2023-506296-97-00
5
2025-10-28
Moderate to Severe Plaque Psoriasis
2024-518365-10-00
5
2025-10-28
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
2024-519081-49-00
4
2025-10-28
Moderate to severe atopic dermatitis
2024-519495-83-00
4
2025-10-28
Digestive system diseases
2024-517140-65-00
9
2025-10-23
Multiple Myeloma (MM).
2024-514110-12-00
7
2025-10-22
Thyroid Eye Disease
2025-520541-72-00
5
2025-10-22
Major Depressive Disorder
2025-520464-17-00
4
2025-10-21
Atherosclerotic Cardiovascular disease
2024-517121-10-00
5
2025-10-17
Menstrual Migraine
2024-517184-23-00
4
2025-10-16
platinum-resistant advanced high-grade epithelial ovarian, primary per
2025-520564-17-00
5
2025-10-16
Hidradenitis suppurativa (HS)
2025-521640-38-00
5
2025-10-16
Focal onset seizures or primary generalized tonic-clonic seizures.
2024-516234-35-00
9
2025-10-15
Relapsed or Refractory B-Cell Malignancies
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
2025-520490-38-00
3
2025-10-13
Haemophilia A with or without inhibitors. Proposed indication under de
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
2023-505323-31-00
5
2025-10-09
Hidradenitis Suppurativa
2024-515682-34-00
5
2025-10-06
Chronic migraine
2024-515715-22-00
5
2025-10-06
Episodic migraine
2024-518714-31-00
5
2025-10-03
Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)
2024-519736-17-00
4
2025-10-03
Hidradenitis Suppurativa
2024-514822-21-00
5
2025-10-02
Platinum-resistant Ovarian Cancer
2025-520499-24-00
5
2025-10-01
Moderate to Severe Platysma Prominence
Showing 433–456 of 1,708 trials